Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Advanced Cancer Therapeutics CEO to Present Preclinical Data on Cancer Metabolism DrugAdvanced Cancer Therapeutics CEO to Present Preclinical Data on Cancer Metabolism Drug at MidAmerica Healthcare Venture Forum
Mr. Riggs will discuss the strides taken by ACT to advance tomorrow’s discoveries in cancer treatment, with a particular focus on PFK-158, ACT’s novel and potent small molecule clinical candidate in the area of cancer metabolism. PFK-158 is a small molecule inhibitor which targets a cancer cell’s ability to consume sugar/glucose, a key fuel source in cancer cell growth and metastasis. PFK-158 is currently undergoing IND-enabling studies in preparation for Phase I human clinical trials. *** About Advanced Cancer Therapeutics (ACT): ACT is a for-profit private company dedicated to advancing novel therapeutics for the prevention and treatment of cancer. ACT has successfully established a unique and innovative business model with the University of Louisville’s James Graham Brown Cancer Center (Brown Cancer Center) whereby ACT is able to obtain exclusive worldwide licenses to novel cancer therapeutics discovered at Brown Cancer Center under preset business terms. ACT then fast-tracks these discoveries, including the selection process for partnership, commercialization and manufacture, to the pharmaceutical industry, and ultimately to the patients who need them. Led by Dr. Don Miller, the Brown Cancer Center employs over fifty leading scientists focused on the discovery and advancement of breakthrough cancer therapeutics for patients suffering from cancer. For more information, please visit www.advancedcancertherapeutics.com. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|